Docket No.: 0020-5458PUS1

## **REMARKS**

The present paper cancels claims 1-17 and replaces them with new claims 18-26. This method of amendment was chosen for its editorial simplicity.

By this amendment:

- 1) reference to a "prodrug" is deleted;
- 2) the definitions of Ar<sup>1</sup> and Ar<sup>2</sup> are amended to be as defined in the specification at page 11, line 3 to page 12, line 4;
  - 3) the ring Z is specified as a substituted pyrrole (2);
- 4) remaining groups and substituents are as described at page 11, line 6 to page 20, line 15 of the specification.

Thus, no new matter is added by any amendment.

## Rejection under 35 USC § 112, first paragraph

Claims 1-9, 11, 13-14 and 17 stand rejected under 35 USC § 112, first paragraph for alleged lack of enabling disclosure. In particular, the Examiner alleges that the term "prodrug" is not enabled, and further that the scope of the compounds encompassed by the claims is far greater than the scope of enablement provided by the specification.

Applicants strongly disagree with the Examiner's assertions. While the Examiner has provided at least some explanation for his objection to the term "prodrug", the Examiner's position on enablement of the scope of the claims with respect to the fundamental structure of the compounds encompassed is presented merely as a conclusion, without any supporting reasoning or evidence.

Nonetheless, solely to advance the prosecution of the present claims, Applicants have amended the claims so as to reduce their scope to that deemed enabled by the Examiner, with the exception that the ring Z includes in its definition that it may be a 1,3 substituted pyrrole in

8

Application No.: 10/563,361 Docket No.: 0020-5458PUS1

Reply to Office Action of November 13, 2007

addition to being a 1,2 substituted pyrrole. The embodiment of a 1,3 substituted pyrrole is

disclosed in Example 51, at page 107 of the present specification and intermediates thereof are

set forth in Reference Examples 6-1 to 6-3 at page 46, line 2 to page 47, line 9 of the

specification. Thus, one of ordinary skill in the art is well-enabled to make these embodiments

of the invention.

Applicants reserve the right to file an application directed to the subject matter canceled

from the present application pursuant to 35 USC § 120.

The sole issue precluding allowance of the claims has been addressed as explained above.

Accordingly, withdrawal of the standing rejections and prompt allowance of the now-pending

claims are respectfully requested.

Should there be any outstanding matters that need to be resolved in the present

application, the Examiner is respectfully requested to contact Mark J. Nuell, Ph.D. (Reg. No.

36,623) at the telephone number of the undersigned below, to conduct an interview in an effort

to expedite prosecution in connection with the present application.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies

to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional

fees required under 37.C.F.R. §§1.16 or 1.14; particularly, extension of time fees.

Dated: February 13, 2008

Respectfully submitted,

By my/ Dell Mark J. Muell, Ph.D.

Registration No.: 36,623

BIRCH, STEWART, KOLASCH & BIRCH, LLP

12770 High Bluff Drive – ste 260

San Diego, CA 92130

858-792-8855

Attorney for Applicant

9

DRN/kpc